Post-transplant lymphoproliferative disorders.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer treatment and research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-319-13150-4_13PMID 25655616
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era

  2014cited by this paper
• Adapted Treatment of Epstein–Barr Virus Infection to Prevent Posttransplant Lymphoproliferative Disorder After Heart Transplantation

  2014cited by this paper
• Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

  2013cited by this paper
• Post-Transplant Lymphoproliferative Disease (PTLD): Risk Factors, Diagnosis, and Current Treatment Strategies

  2013cited by this paper
• EBV and posttransplantation lymphoproliferative disease: what to do?

  2013cited by this paper
• Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score.

  2013cited by this paper
• Low‐Dose Chemotherapy and Rituximab for Posttransplant Lymphoproliferative Disease (PTLD): A Children's Oncology Group Report

  2012cited by this paper
• Interim analysis of the largest prospective trial to date in adult CD20-positive post-transplant lymphoproliferative disorder (PTLD): Introducing risk-stratified sequential treatment (RSST).

  2012cited by this paper
• Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.

  2012cited by this paper
• Post Transplant Lymphoproliferative Disorders: Risk, Classification, and Therapeutic Recommendations

  2012cited by this paper
• Burkitt post‐transplantation lymphoma in adult solid organ transplant recipients

  2012cited by this paper
• Epstein–Barr Virus‐Related Post‐Transplant Lymphoproliferative Disorders: Pathogenetic Insights for Targeted Therapy

  2011cited by this paper
• Association of HLA Polymorphisms with Post‐transplant Lymphoproliferative Disorder in Solid‐Organ Transplant Recipients

  2011cited by this paper
• Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder ★

  2011cited by this paper
• Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: A remission induction therapy for aggressive pediatric post‐transplant lymphoproliferative disease (PTLD)

  2011cited by this paper
• Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

  2010cited by this paper
• Primary central nervous system post‐transplantation lymphoproliferative disorder

  2010cited by this paper
• Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

  2010cited by this paper
• Diagnosis of post‐transplant lymphoproliferative disorder in solid organ transplant recipients – BCSH and BTS Guidelines

  2010cited by this paper
• Management of post‐transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS Guidelines

  2010cited by this paper
• Chronic high Epstein–Barr viral load carriage in pediatric small bowel transplant recipients

  2009cited by this paper
• Chronic high Epstein‐Barr viral load carriage in pediatric liver transplant recipients

  2009cited by this paper
• Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease

  2009cited by this paper
• Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.

  2009cited by this paper
• Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.

  2009cited by this paper
• Quantitative Epstein-Barr virus viral load monitoring in pediatric liver transplantation.

  2008cited by this paper
• Successful treatment of a child with late onset T‐cell post‐transplant lymphoproliferative disorder/lymphoma

  2008cited by this paper
• Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder

  2008cited by this paper
• Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant

  2008cited by this paper
• Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease

  2007cited by this paper
• Dissociation of Depletional Induction and Posttransplant Lymphoproliferative Disease in Kidney Recipients Treated With Alemtuzumab

  2007cited by this paper
• Efficacy and tolerability of high‐dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children

  2007cited by this paper
• A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies.

  2007cited by this paper
• Evidence for Genetic Susceptibility Towards Development of Posttransplant Lymphoproliferative Disorder in Solid Organ Recipients

  2007cited by this paper
• CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.

  2007cited by this paper
• Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution

  2007cited by this paper
• Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.

  2007cited by this paper
• Long‐term survival in post‐transplant lymphoproliferative disorders with a dose‐adjusted ACVBP regimen

  2006cited by this paper
• Post‐Transplant Lymphoproliferative Disorders Occurring After Renal Transplantation in Adults: Report of 230 Cases From the French Registry

  2006cited by this paper
• Preemptive diagnosis and treatment of Epstein–Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development

  2006cited by this paper
• The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.

  2006cited by this paper
• Review of Epstein–Barr virus and post‐transplant lymphoproliferative disorder post‐solid organ transplantation (Review Article)

  2006cited by this paper
• Use of cytokine polymorphisms and Epstein–Barr virus viral load to predict development of post‐transplant lymphoproliferative disorder in paediatric liver transplant recipients

  2006cited by this paper
• Association of Human Leukocyte Antigen Haplotypes with Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation

  2006cited by this paper
• Treatment of PTLD with Rituximab or Chemotherapy

  2006cited by this paper
• Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.

  2006cited by this paper
• Rituximab (Chimeric Anti-CD20 Antibody) for Posttransplant Lymphoproliferative Disorder after Solid Organ Transplantation in Adults: Long-Term Experience from a Single Center

  2005cited by this paper
• Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation

  2005cited by this paper
• Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.

  2005cited by this paper
• Posttransplant Lymphoproliferative Disorders after Renal Transplantation in the United States in Era of Modern Immunosuppression

  2005cited by this paper
• Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era

  2005cited by this paper
• Posttransplant lymphoproliferative disorder: significance of central nervous system involvement.

  2005cited by this paper
• Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.

  2005cited by this paper
• Interferon gamma (IFN-gamma) polymorphism in posttransplantation lymphoproliferative disease.

  2005cited by this paper
• Effect of Anti‐CD 20 Antibody Rituximab in Patients with Post‐Transplant Lymphoproliferative Disorder (PTLD)

  2005cited by this paper
• HLA Antigens and Post Renal Transplant Lymphoproliferative Disease: HLA-B Matching Is Critical

  2005cited by this paper
• Mini‐BEAM and autologous hematopoietic stem‐cell transplant for treatment of post‐transplant lymphoproliferative disorders

  2005cited by this paper
• Post-transplant lymphoproliferative disorders.

  2005cited by this paper
• Quantitative EBV Viral Loads and Immunosuppression Alterations can Decrease PTLD Incidence in Pediatric Liver Transplant Recipients

  2005cited by this paper
• Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report

  2004cited by this paper
• Adult Burkitt leukemia and lymphoma.

  2004cited by this paper
• Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.

  2004cited by this paper
• Post Transplant T‐Cell Lymphoma: A Case Series of Four Patients from a Single Unit and Review of the Literature

  2004cited by this paper
• The role of immunosuppression in lymphoma formation

  2004cited by this paper
• High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment

  2003cited by this paper
• Post-transplant Burkit t's Leukemia or Lymphoma. Study of Five Cases Treated with Specific Intensive Therapy (PETHEMA ALL-3/97 Trial)

  2003cited by this paper
• Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease.

  2003cited by this paper
• Tumors and Transplantation: The 2003 Third Annual ASTS State‐of‐the‐Art Winter Symposium

  2003cited by this paper
• Lymphoproliferative disorders in Oxford renal transplant recipients

  2003cited by this paper
• A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation.

  2003cited by this paper
• Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University.

  2003cited by this paper
• Successful Treatment of Posttransplant Lymphoproliferative Disorder in a Renal Transplant Patient by Autologous Peripheral Blood Stem Cell Transplantation

  2002cited by this paper
• Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients

  2002cited by this paper
• Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication.

  2002cited by this paper
• Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome

  2002cited by this paper
• REDUCTION IN IMMUNOSUPPRESSION AS INITIAL THERAPY FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: ANALYSIS OF PROGNOSTIC VARIABLES AND LONG-TERM FOLLOW-UP OF 42 ADULT PATIENTS1

  2001cited by this paper
• Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial.

  2001cited by this paper
• A gene polymorphism associated with posttransplant lymphoproliferative disorder.

  2001cited by this paper
• Rising incidence of post‐transplant lymphoproliferative disease in kidney transplant recipients

  2001cited by this paper
• Epstein–Barr virus post‐transplant lymphoproliferative disease and virus‐specific therapy: pharmacological re‐activation of viral target genes with arginine butyrate

  2001cited by this paper
• Identifying the patient at risk for post‐transplant lymphoproliferative disorder

  2001cited by this paper
• RISK FACTORS FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD) IN PEDIATRIC KIDNEY TRANSPLANTATION: A REPORT OF THE NORTH AMERICAN PEDIATRIC RENAL TRANSPLANT COOPERATIVE STUDY (NAPRTCS)1

  2001cited by this paper
• Post renal transplantation human herpesvirus 8‐associated lymphoproliferative disorder and Kaposi's sarcoma

  2001cited by this paper
• Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders.

  2001cited by this paper
• The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.

  2000cited by this paper
• Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant.

  2000cited by this paper
• Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?

  2000cited by this paper
• Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.

  2000cited by this paper
• Post‐transplantation lymphoproliferative disease of natural killer cell lineage: a clinicopathological and molecular analysis

  2000cited by this paper
• Risk of lymphoid neoplasia after cardiothoracic transplantation. a cohort study of the relation to Epstein-Barr virus.

  2000cited by this paper
• Lymphoproliferative disorders in heart transplant recipients: role of hepatitis C virus (HCV) and Epstein‐Barr virus (EBV) infection

  2000cited by this paper
• The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.

  2000cited by this paper
• Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.

  1999cited by this paper
• Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants.

  1998cited by this paper
• Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users.

  1998cited by this paper
• Posttransplantation lymphoproliferative disorder associated with OKT3 and decreased antiviral prophylaxis in pancreas transplant recipients.

  1998cited by this paper
• Epstein-Barr virus-induced T cell lymphoma in solid organ transplant recipients.

  1998cited by this paper
• BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome.

  1998cited by this paper
• Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients.

  1997cited by this paper
• Incidence and consequences of post-transplantation lymphoproliferative disorders.

  1997cited by this paper

• Incidence and outcomes of post‐transplant lymphoproliferative disorder in the Western Australian liver transplant population: a 24‐year retrospective study

  2025cites this paper
• Clinical Features of Pulmonary Lymphoproliferative Disorders.

  2025cites this paper
• A Case of Post-transplant Lymphoproliferative Disorder After Successful Treatment of Islet Transplantation Without Graft Rejection

  2025cites this paper
• A Post-transplant Immunosuppression Complication: Epstein-Barr Virus-Positive Classic Hodgkin Lymphoma Post-transplant Lymphoproliferative Disorder

  2025cites this paper
• Incidence and Management of Posttransplantation Lymphoproliferative Disorder After Pediatric Solid Organ Transplantation: The Norwegian Experience

  2025cites this paper
• Membrane‐bound CD95 ligand modulates CD19‐mediated B cell receptor signaling and EBV activation

  2024cites this paper
• Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation

  2024cites this paper
• The Post-transplant Lymphoproliferative Disorders—Metagenomic Shotgun Microbial Sequencing (PTLD-MSMS) Study Methods and Protocol

  2024cites this paper
• [A case of primary central nervous system post-transplant lymphoproliferative disease 14 years after living donor liver transplantation].

  2024cites this paper
• Metachronous spinal cord involvement B cell and subcutaneous tissue involvement NK/T cell lymphoid proliferations and lymphomas arising in post-transplantation mimicking general NK/T cell lymphoma: a case report and review of the literature

  2024cites this paper
• Diagnostic and Therapeutic Challenge: Posterior Scleritis.

  2023cites this paper
• Clinical, Radiological and Histopathological Evaluation of Primary Colon Lymphoma

  2023cites this paper
• A case of early multifocal posttransplant lymphoproliferative disease in an adult after liver transplantation and literature analysis

  2023cites this paper
• Cutaneous T-Cell Lymphoma (CTCL) Arising Post Kidney Transplant: A Review of Clinical Variants in the Literature

  2023cites this paper
• Anterior Chamber Snowflake After Keratoplasty.

  2023cites this paper
• Immune dysregulation as a leading principle for lymphoma development in diverse immunological backgrounds.

  2023cites this paper
• Incidence and Features of Lymphoid Proliferation and Lymphomas after Solid Organ or Hematopoietic Stem Cell Transplantation in a National Database Cohort

  2023cites this paper
• T cell-mediated immunity during Epstein-Barr virus infections in children.

  2023cites this paper
• Epstein-Barr Virus and Multiple Sclerosis: A Convoluted Interaction and the Opportunity to Unravel Predictive Biomarkers

  2023cites this paper
• A Case of Central Nervous System Post-Transplant Lymphoproliferative Disorder Following Haploidentical Stem Cell Transplantation in a Patient With Acute Lymphoblastic Leukemia

  2022cites this paper
• Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B cell malignancy.

  2022cites this paper
• Human germline biallelic complete NFAT1 deficiency causes the triad of progressive joint contractures, osteochondromas, and susceptibility to B cell malignancy

  2022cites this paper
• Post-Transplant Lymphoproliferative Disease (PTLD) after Allogeneic Hematopoietic Stem Cell Transplantation: Biology and Treatment Options

  2022influential citation
• Post-transplant lymphoproliferative disease after pediatric kidney transplant

  2022cites this paper
• Analysis of Post-Transplant Lymphoproliferative Disorder (PTLD) Outcomes with Epstein–Barr Virus (EBV) Assessments—A Single Tertiary Referral Center Experience and Review of Literature

  2021cites this paper
• A Rare Case of Disseminated Tuberculosis and Hematological Malignancy in a Heart Transplant Recipient.

  2021cites this paper
• Infectious complications during immunochemotherapy of post-transplantation lymphoproliferative disease–can we decrease the risk? Two case reports and review of literature

  2021cites this paper
• Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report

  2021cites this paper
• De Novo Malignancies After Liver Transplantation: Experience of a High-Volume Center

  2021influential citation
• A rare case of metastatic uterine lymphoma in a renal transplant patient.

  2021cites this paper
• Stress-Induced Epstein-Barr Virus Reactivation

  2021cites this paper
• Cancers associated with human gammaherpesviruses

  2021cites this paper
• Management of Epstein–Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation

  2020cites this paper
• Impact assessment and investigation of factors associated with herpesviruses viremia in the first year of renal transplantation

  2020cites this paper
• Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplant.

  2020cites this paper
• Cross-cutting view of current challenges in paediatric solid organ and haematopoietic stem cell transplantation in Europe: the European Reference Network TransplantChild

  2020cites this paper
• Pathobiology and Treatment of Lymphomatoid Granulomatosis; A Rare EBV-Driven Disorder.

  2020cites this paper
• Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs

  2020cites this paper
• Anaplastic large cell lymphoma as a posttransplant lymphoproliferative disorder in a renal transplant patient: A case report

  2020cites this paper
• Trastornos linfoproliferativos en una cohorte de pacientes adultos con trasplante hepático atendidos en un hospital de referencia en Bogotá, Colombia

  2020cites this paper
• De novo and recurrent malignancy.

  2020cites this paper
• Toll-like receptor-mediated innate immunity against herpesviridae infection: a current perspective on viral infection signaling pathways

  2020cites this paper
• Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations

  2020cites this paper
• Post-transplant lymphoproliferative disorders in a cohort of adult patients with a liver transplant from a reference hospital in Bogotá, Colombia

  2020cites this paper
• Safety and Efficacy of CAR T-Cell Therapy in Kidney Transplant Recipients.

  2020cites this paper
• Various initial presentations of Epstein‐Barr virus infection‐associated post‐transplant lymphoproliferative disorder in pediatric liver transplantation recipients: Case series and literature review

  2019cites this paper
• Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention: Hepatitis viruses, human T-cell leukemia viruses, herpesviruses, and Epstein-Barr virus.

  2019cites this paper
• Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield

  2019cites this paper
• Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: a review.

  2019cites this paper
• Clinical and Radiographic Characteristics of Sinonasal Posttransplant Lymphoproliferative Disorder and Invasive Fungal Sinusitis

  2019cites this paper
• Posttransplant Lymphoproliferative Disorder in Adults Receiving Kidney Transplantation in British Columbia: A Retrospective Cohort Analysis

  2018cites this paper
• Nasopharyngeal Swelling in a Patient With Cystic Fibrosis Following Endoscopic Sinus Surgery.

  2018cites this paper
• Comprehensive review of post–organ transplant hematologic cancers

  2018cites this paper
• Face allotransplantation for various types of facial disfigurements: A series of five cases

  2018cites this paper
• Treatment dilemma for survivors of rituximab-induced bowel perforation in the setting of post-transplant lymphoproliferative disorder

  2018cites this paper
• Central Nervous System Infections in Patients Receiving Cancer Therapies

  2018cites this paper
• Pediatric Gastrointestinal Posttransplant Lymphoproliferative Disorder: Incidence, Clinical Characteristics, and Impact of Major Surgical Interventions Upon Overall Survival

  2018cites this paper
• Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation.

  2018cites this paper
• Peripheral Blood Epstein–Barr Viral Nucleic Acid Surveillance as a Marker for Posttransplant Cancer Risk

  2017cites this paper
• Consideration of difficulties and exit strategies in a case of face allotransplantation resulting in failure

  2017cites this paper
• B-cell posttransplant lymphoproliferative disorder isolated to the central nervous system is Epstein-Barr virus positive and lacks p53 and Myc expression by immunohistochemistry.

  2017cites this paper
• Oral Complications of Nonsurgical Cancer Therapies.

  2017cites this paper
• The Safety of Allogeneic Stem Cell Transplantation

  2017cites this paper
• Epstein-Barr Virus

  2017cites this paper
• B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency: 2015 SH/EAHP Workshop Report—Part 2

  2017cites this paper
• The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion

  2017cites this paper
• Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature

  2017cites this paper
• Post-transplant lymphoproliferative disorders

  2016cites this paper
• EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations

  2016cites this paper
• The influence of intrauterine exposure to immunosuppressive treatment on changes in the immune system in juvenile Wistar rats

  2016cites this paper
• Title: Post renal transplant lymphoma

  2016cites this paper
• Post-transplant Lymphoproliferative Disorder (PTLD): Infection, Cancer?

  2016cites this paper
• Epstein-Barr Virus–related Posttransplant Lymphoproliferative Disorder in Children: A Single-institution Experience

  2016cites this paper
• Case Report: Multivisceral Transplantation for an Extensive Cystic Lymphangioma of the Mesenteric Root.

  2016cites this paper
• Post-renal transplant lymphoma.

  2016cites this paper
• Lymphoma in Danon disease with chronic rhabdomyolysis treated with EPOCH-R

  2016cites this paper
• Gastric Mucosa-associated Lymphoid Tissue Lymphoma: Posttransplant Lymphopoliferative Disorder.

  2016cites this paper
• Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy

  2015cites this paper
• Tumor Suppressor Interferon-Regulatory Factor 1 Counteracts the Germinal Center Reaction Driven by a Cancer-Associated Gammaherpesvirus

  2015cites this paper
• Subacute Imbalance in a Renal Transplant Patient.

  2015cites this paper
• Development of an algorithm for the management of cervical lymphadenopathy in children: consensus of the Italian Society of Preventive and Social Pediatrics, jointly with the Italian Society of Pediatric Infectious Diseases and the Italian Society of Pediatric Otorhinolaryngology

  2015cites this paper
• The safety of calcineurin inhibitors for kidney-transplant patients

  2015cites this paper